Natera Partners with One Lambda to Distribute Kidney Transplant Rejection Test

Natera said today that it has struck a distribution deal with Thermo Fisher Scientific’s One Lamda to co-distribute its cell-free DNA-based kidney transplant rejection test in the US.

The company published a validation study of its kidney transplant rejection assay in the Journal of Clinical Medicine last December, retrospectively analyzing 300 plasma samples from 193 patients. Last month, Natera said that it had submitted a dossier to the Centers for Medicare and Medicaid Services for reimbursement and anticipated that its test would be priced at a similar rate to CareDx’s cfDNA assay for kidney transplant rejection of $2,800.

Source: https://www.genomeweb.com/sequencing/natera-partners-one-lambda-distribute-kidney-transplant-rejection-test